S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Safest Option in Trades! (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel

NeuroBo Pharmaceuticals - NRBO Stock Forecast, Price & News

$0.40
0.00 (0.00%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.40
50-Day Range
$0.36
$0.58
52-Week Range
$0.34
$4.95
Volume
42,254 shs
Average Volume
112,487 shs
Market Capitalization
$10.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

NeuroBo Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,909.0% Upside
$16.00 Price Target
Short Interest
Healthy
1.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.88mentions of NeuroBo Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

224th out of 1,117 stocks

Pharmaceutical Preparations Industry

106th out of 550 stocks

NRBO stock logo

About NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

NeuroBo Pharmaceuticals Stock Performance

NRBO Stock remained flat at $0.40 during trading on Friday. The company's stock had a trading volume of 42,254 shares, compared to its average volume of 112,487. The company has a 50-day moving average price of $0.47 and a two-hundred day moving average price of $0.66. NeuroBo Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $4.95.

NeuroBo Pharmaceuticals (NASDAQ:NRBO - Get Rating) last released its quarterly earnings data on Friday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. On average, sell-side analysts forecast that NeuroBo Pharmaceuticals will post -0.7 EPS for the current fiscal year.

Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRBO Stock News Headlines

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Trading Down 4%
VOD, UL and MBOT among pre market gainers
NeuroBo Pharmaceuticals Inc.
See More Headlines
Receive NRBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRBO Company Calendar

Last Earnings
11/15/2021
Today
8/13/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRBO
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+3,909.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.55 per share

Miscellaneous

Free Float
19,223,000
Market Cap
$10.64 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Dr. Ben Gil Price M.D. (Age 66)
    CEO & Pres
    Comp: $529.23k
  • Dr. Matthew Bardin BCPS
    Pharm.D., Sr. VP of Operations
  • Mr. Frank Kondrad
    VP of Corp. & Bus. Devel.
  • Dr. Andrew Bartynski Ph.D.
    Sr. VP













NRBO Stock - Frequently Asked Questions

Should I buy or sell NeuroBo Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRBO shares.
View NRBO analyst ratings
or view top-rated stocks.

What is NeuroBo Pharmaceuticals' stock price forecast for 2022?

1 Wall Street research analysts have issued twelve-month price objectives for NeuroBo Pharmaceuticals' stock. Their NRBO share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 3,909.0% from the stock's current price.
View analysts price targets for NRBO
or view top-rated stocks among Wall Street analysts.

How have NRBO shares performed in 2022?

NeuroBo Pharmaceuticals' stock was trading at $1.22 on January 1st, 2022. Since then, NRBO stock has decreased by 67.3% and is now trading at $0.3991.
View the best growth stocks for 2022 here
.

When is NeuroBo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our NRBO earnings forecast
.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

What is NeuroBo Pharmaceuticals' stock symbol?

NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO."

Who are NeuroBo Pharmaceuticals' major shareholders?

NeuroBo Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroBo Pharmaceuticals' stock price today?

One share of NRBO stock can currently be purchased for approximately $0.40.

How much money does NeuroBo Pharmaceuticals make?

NeuroBo Pharmaceuticals (NASDAQ:NRBO) has a market capitalization of $10.64 million. The company earns $-15,280,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. The official website for the company is www.neurobopharma.com. The company can be reached via phone at (857) 702-9600, via email at mmiller@rxir.com, or via fax at 734-293-0444.

This page (NASDAQ:NRBO) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.